SELLAS Life Sciences Group Quarterly Balance Sheet
NASDAQ: SLSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
SELLAS Life Sciences Group financial position
As of Jun 30, 2026, SELLAS Life Sciences Group reported total assets of $145.4 million, up 350.0% from a year earlier against total liabilities of $7.7 million. Shareholders' equity stood at $137.7 million, or 94.7% of assets. The company held $138.3 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 18.83, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
SELLAS Life Sciences Group balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 138.34M | 107.10M | 71.79M | 44.32M | 25.30M | 28.40M | 13.89M | 21.03M | 9.15M | 18.41M | 2.53M | 3.97M |
| Total Current Assets | 142.50M | 111.17M | 75.21M | 49.05M | 29.45M | 31.97M | 16.33M | 24.04M | 12.30M | 21.50M | 3.17M | 5.20M |
| Goodwill | 1.91M | 1.91M | 1.91M | 1.91M | 1.91M | 1.91M | 1.91M | 1.91M | 1.91M | 1.91M | 1.91M | 1.91M |
| Total Assets | 145.38M | 114.18M | 78.34M | 51.55M | 32.30M | 34.96M | 19.43M | 26.50M | 15.12M | 24.43M | 6.22M | 8.09M |
| Accounts Payable | 3.09M | 3.63M | 2.95M | 2.31M | 3.34M | 3.76M | 3.50M | 4.55M | 6.33M | 7.41M | 5.64M | 4.34M |
| Total Current Liabilities | 7.57M | 6.46M | 7.02M | 5.92M | 6.00M | 6.89M | 9.51M | 10.61M | 12.04M | 14.44M | 13.73M | 11.73M |
| Total Liabilities | 7.73M | 6.76M | 7.47M | 5.92M | 6.16M | 7.20M | 9.97M | 10.61M | 12.21M | 14.75M | 14.20M | 11.91M |
| Shareholders' Equity | 137.66M | 107.41M | 70.87M | 45.63M | 26.15M | 27.76M | 9.46M | 15.89M | 2.91M | 9.68M | -7.98M | -3.83M |
| Retained Earnings | -293.00M | -283.39M | -274.99M | -267.33M | -260.54M | -253.94M | -248.13M | -241.39M | -234.28M | -226.81M | -217.24M | -209.11M |
| Net Cash (Debt) | 138.34M | 107.10M | 71.79M | 44.32M | 25.30M | 28.40M | 13.89M | 21.03M | 9.15M | 18.41M | 2.53M | 3.97M |
| Shares Outstanding | 201.92M | 181.33M | 153.10M | 125.08M | 100.37M | 90.90M | 73.98M | 64.38M | 57.75M | 56.27M | 32.13M | 28.39M |
This table shows 12 quarterly periods of SELLAS Life Sciences Group's balance sheet, from Q2 2026 back to Q3 2023, across 17 line items including cash & equivalents, receivables, inventory. Values in USD; B = billions, M = millions. Fiscal periods follow SLS's reporting calendar. What is a balance sheet?